Heparan sulfate accumulation and perlecan/HSPG2 up-regulation in tumour tissue predict low relapse-free survival for patients with glioblastoma

Galina M. Kazanskaya, Alexandra Y. Tsidulko, Alexander M. Volkov, Roman S. Kiselev, Anastasia V. Suhovskih, Vyacheslav V. Kobozev, Alexei S. Gaytan, Svetlana V. Aidagulova, Alexei L. Krivoshapkin, Elvira V. Grigorieva

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

Glycosaminoglycans are major components of brain extracellular matrix (ECM), although heparan sulfate (HS) contribution in brain physiology and carcinogenesis remains underinvestigated. This study examined HS content and distribution in glioblastoma multiforme (GBM) tissues in the context of potential molecular mechanisms underlying its deregulation in brain tumours. Totally, 42 tissue samples and paraffin-embedded tissues for 31 patients with different prognosis were investigated. HS expression was demonstrated in 50–55% of the GBM tumours by immunohistochemistry (IHC), while almost no HS content was detected in the surrounding paratumourous brain tissues. Heterogeneous HS distribution in the HS-positive tumours was more related to the necrosis or glandular-like brain zones rather than glioma cells with high or low Ki-67 index. According the Kaplan–Meier curves, HS accumulation in glioma cells was associated with low relapse-free survival (RS) of the GBM patients (p < 0.05) and was likely to be due to the increased transcriptional activity of HSPG core proteins (syndecan-1, 2–3 fold; glypican-1, 2,5 fold; perlecan/HSPG2, 13–14 fold). Activation of perlecan/HSPG2 expression correlated with the patients’ survival according Kaplan–Meier (p = 0.0243) and Cox proportional-hazards regression (HR = 3.1; P(Y) = 0.03) analyses, while up-regulation of syndecan-1 and glypican-1 was not associated with the patients survival. Taken together, the results indicate that increase of HS content and up-regulation of perlecan/HSPG2 expression in glioblastoma tissues contribute to tumour development through the transformation of brain extracellular matrix into tumour microenvironment, and represent negative prognostic factors for glioblastoma progression.

Original languageEnglish
Pages (from-to)235-244
Number of pages10
JournalHistochemistry and Cell Biology
Volume149
Issue number3
DOIs
Publication statusPublished - 1 Mar 2018

Keywords

  • Glioblastoma
  • Glypican-1
  • Heparan sulfate
  • Perlecan/HSPG2
  • Proteoglycan
  • Syndecan-1
  • NERVOUS-SYSTEM
  • LOCALIZATION
  • PROTEOGLYCANS
  • GLYCOSAMINOGLYCANS
  • ANGIOGENESIS
  • GLIOMA-CELL INVASION
  • BRAIN-DEVELOPMENT
  • IN-VITRO
  • EXTRACELLULAR-MATRIX
  • EXPRESSION

Fingerprint

Dive into the research topics of 'Heparan sulfate accumulation and perlecan/HSPG2 up-regulation in tumour tissue predict low relapse-free survival for patients with glioblastoma'. Together they form a unique fingerprint.

Cite this